Latest News about BEAM
Recent news which mentions BEAM
From Benzinga
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage
July 18, 2022
From Benzinga
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
From InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
From InvestorPlace
From Benzinga
From Motley Fool
3 Cathie Wood Stocks That Could Deliver Monster Returns
June 04, 2022
From Motley Fool
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Friday
April 08, 2022
From Benzinga
2 Reasons Why Pfizer Might Crush Moderna in the mRNA Market. And 1 Reason Why Moderna May Stay Ahead.
February 17, 2022
From Motley Fool
2 Exciting Trends That Could Shape Healthcare's Future
February 10, 2022
From Motley Fool
Here's What to Look For in Pfizer's Upcoming Earnings Report
January 25, 2022
From Motley Fool
Why Pfizer's Deal With Beam Therapeutics Is a Smart Move
January 23, 2022
From Motley Fool
Moderna Is Betting on a New Way to Fight Cancer
January 23, 2022
From Motley Fool
From Motley Fool
Why Is Pfizer Teaming Up With Acuitas Therapeutics?
January 22, 2022
From Motley Fool
Is Beam Therapeutics a Good Stock to Buy Now?
January 16, 2022
From Motley Fool
Why Editas Medicine Stock Is Tumbling This Week
January 13, 2022
From Motley Fool
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
January 10, 2022
From Benzinga
My 3 Top Biotech Stock Picks for 2022
January 09, 2022
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
January 05, 2022
From Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
From InvestorPlace
8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022
December 07, 2021
From Motley Fool
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
From Motley Fool
Direxion Launches New Nanotechnology ETF, TYNE
November 23, 2021
From ETF Trends
Being First Is Not Enough For Crispr Therapeutics
November 15, 2021
From InvestorPlace
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
November 12, 2021
Tickers
BEAM
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.